Clinical trial
A Randomised Double Blind Placebo Controlled Phase II Study of Fulvestrant With or Without the Addition of Vandetanib as Treatment for Patients With Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy
NCT02530411 is registered in ClinicalTrials.gov with Velindre NHS Trust as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomised Double Blind Placebo Controlled Phase II Study of Fulvestrant With or Without the Addition of Vandetanib as Treatment for Patients With Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy
- Lead sponsor
- Velindre NHS Trust
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- April 30, 2015
- Completion date
- December 31, 2020
- Enrollment
- 160 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.